IJC metabolic & endocrine最新文献_第10页

Complement C3c and C4c as predictors of death in heart failure 补体C3c和C4c作为心力衰竭死亡的预测因子

IJC metabolic & endocrine Pub Date : 2015-06-01 DOI: 10.1016/j.ijcme.2015.02.001

Nuno Silva , Sandra Martins , Patrícia Lourenço , Paulo Bettencourt , João Tiago Guimarães

{"title":"Complement C3c and C4c as predictors of death in heart failure","authors":"Nuno Silva , Sandra Martins , Patrícia Lourenço , Paulo Bettencourt , João Tiago Guimarães","doi":"10.1016/j.ijcme.2015.02.001","DOIUrl":"10.1016/j.ijcme.2015.02.001","url":null,"abstract":"<div><h3>Background</h3><p>Activation of the immune system is one of the several pathways suggested as involved in Heart Failure (HF). The complement system is a key component of innate immunity. We hypothesized that complement proteins C3 and C4 can be an important predictor of death in patients with this condition.</p></div><div><h3>Methods</h3><p>380 patients admitted with acute HF were recruited. They were followed up during 6months. Serum C3c and C4c proteins were measured and groups were created and compared according to the 25th percentile cut-off value. A multivariate Cox-regression model was used to establish the prognostic value of both markers with the endpoints of HF and all-cause death.</p></div><div><h3>Results</h3><p>Median patients' age was 78years and 49% of the patients were men. No major differences were observed in clinical characteristics of the groups. Patients with lower values of C3c and C4c had significantly higher values of BNP. During the 6 month period of follow up, 63 patients died, and 49 patients were due to HF. C4c showed univariate prognostic value, but not multivariate value. The multivariate-adjusted Hazard Ratios for the 6month HF and all-cause death in patients with C3c values below 110.0mg/dL were, respectively, 2.32 (95% CI: 1.25–4.28) and 2.52 (95% CI: 1.41–4.49).</p></div><div><h3>Conclusion</h3><p>Lower C3c levels are independently associated with higher risk of death. Our results reinforce the role of innate immunity in HF pathophysiology.</p></div>","PeriodicalId":73333,"journal":{"name":"IJC metabolic & endocrine","volume":"7 ","pages":"Pages 31-35"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijcme.2015.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82330836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Innovative therapeutic approaches for the treatment of myocardial ischemia and angina 创新治疗心肌缺血和心绞痛的方法

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.011

Claudio Ceconi MD

引用次数: 0

The cross talk between oxyLDL and inflammation in atherosclerosis oxyLDL与动脉粥样硬化炎症的串扰

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.006

Naga Venkata Pothineni MD , Zufeng Ding PhD , Sotirios K. Karathanasis PhD , Jawahar Mehta

引用次数: 0

Pharmacodynamic effects of atorvastatin vs. rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy — The PEARL randomized cross-over study 阿托伐他汀与瑞舒伐他汀对双重抗血小板治疗时血小板反应性正常的冠状动脉病患者的药效学影响——PEARL随机交叉研究

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.018

Francesco Pelliccia, Giuseppe Marazzi, Vincenzo Pasceri, Marina Polacco, Luigi Mattioli, Cesare Greco, Carlo Gaudio

引用次数: 0

Fenoldopam for prevention of Acute kidNey injury in patients with aCute coronarY syndrome undergoing coronary angiography and/or percutaneous coronary Intervention — The FANCY trial 非诺多泮预防急性冠状动脉综合征患者接受冠状动脉造影和/或经皮冠状动脉介入治疗的急性肾损伤——FANCY试验

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.021

Christian Pristipino, Vincenzo Pasceri, Antonino Granatelli, Giulio Speciale, Adriana Roncella, Giuseppe Richichi Francesco Pelliccia

引用次数: 0

A modern approach in cardiometabolic risk — The role of oxidative stress and LOX-1 expression in endothelial dysfunction and cardiometabolic risk 心脏代谢风险的现代方法-氧化应激和LOX-1表达在内皮功能障碍和心脏代谢风险中的作用

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.005

Vincenzo Mollace MD

引用次数: 0

Natural antioxidants: A novel approach for counteracting cardiometabolic risk 天然抗氧化剂:一种对抗心脏代谢风险的新方法

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.004

Micaela Gliozzi

引用次数: 0

Transcriptional control of ICAM-1 in human coronary artery endothelial cells by Mineralocorticoid Receptor (MR): Implications for the protective effects of MR antagonists in cardiovascular diseases 矿化皮质激素受体(MR)对人冠状动脉内皮细胞中ICAM-1的转录控制:MR拮抗剂对心血管疾病的保护作用

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.013

V. Marzolla , A. Armani , A. Fabbri , I.Z. Jaffe , M. Caprio

引用次数: 0

Ranolazine reduces symptoms of palpitations and documented arrhythmias in patients with ischemic heart disease — The RYPPLE randomized cross-over trial 雷诺嗪可减轻缺血性心脏病患者心悸和记录的心律失常症状——RYPPLE随机交叉试验

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.016

Francesco Pelliccia, Giuseppe Campolongo, Rosalba Massaro, Vincenzo Pasceri, Cesare Greco, Carlo Gaudio

引用次数: 2

Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy — The PORTO Trial 匹伐他汀与阿托伐他汀对双重抗血小板治疗的冠心病患者血小板反应性的药效学比较——PORTO试验

IJC metabolic & endocrine Pub Date : 2015-05-01 DOI: 10.1016/j.ijcme.2015.05.019

Francesco Pelliccia, Giuseppe Marazzi, Vincenzo Pasceri, Marina Polacco, Michele Schiariti, Cesare Greco, Carlo Gaudio

引用次数: 0